Topics
Glioblastoma | Treatment | Clinical trials | Pembrolizumab
Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > Pembrolizumab
Bagley SJ, Binder ZA, Lamrani L,
Marinari E, Desai AS, Nasrallah MP, Maloney E, Brem S, Lustig RA,
Kurtz G, Alonso-Basanta M, Bonté PE, Goudot C, Richer W,
Piaggio E, Kothari S, Guyonnet L, Guerin CL, Waterfall JJ, Mohan
S, Hwang WT, Tang OY, Logun M, Bhattacharyya M, Markowitz K,
Delman D, Marshall A, Wherry EJ, Amigorena S, Beatty GL, Brogdon
JL, Hexner E, Migliorini D, Alanio C, O'Rourke DM.
Repeated
peripheral infusions of anti-EGFRvIII CAR T cells in combination
with pembrolizumab show no efficacy in glioblastoma: a phase 1
trial.
Nat
Cancer. 2024 Jan
12. doi:
10.1038/s43018-023-00709-6. PMID:
38216766. Interventional study˰ ˍ
Iwamoto FM, Tanguturi SK, Nayak L, Wang TJ, Desai A, Lustig RA,
Bagley S, Wong ET, Hertan LM, McCluskey C, Hayden J, Muzikansky A,
Nakhawa S, Japo J, Bossi CC, Meylan M, Tian Y, Barlow GL,
Speliakos P, Ayoub G, Meredith DM, Ligon KL, Haas-Kogan D, Huang
K, Wucherpfennig KW, Wen PY, Reardon DA.
Re-irradiation
plus pembrolizumab: Phase II study
for recurrent glioblastoma patients.
Clin
Cancer Res. 2024 Nov 8.
doi:
10.1158/1078-0432.CCR-24-1629. PMID:
39513953. Interventional study˰
ˍ